細胞周期素D1(CCND1)單克隆抗體
Monoclonal Antibody to Cyclin D1 (CCND1)
CCN-D1; BCL1; PRAD1; U21B31; G1/S-Specific Cyclin-D1; Parathyroid Adenomatosis 1; B-Cell CLL/Lymphoma 1; G1/S-Specific Cyclin D1; PRAD1 oncogene
- 編號MAA585Hu22
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 來源單抗制備
- 宿主小鼠
- 效價(克隆號)-
- Ig亞型 IgG
- 純化方式抗原特異性親和純化
- 標記物無標記物
- 免疫原 -
- 緩沖液成份磷酸鹽緩沖液（pH7.4,含有0.02% NaN3和50%甘油）
- 性狀液體
- 濃度1mg/mL
- 且適物種-
- 應用WB; IHC; ICC; IP.
如果抗體需用于流式細胞術，請參見流式抗體。 - 下載 英文說明書 中文說明書
- 規格 20μl100μl 200μl 1ml 10ml
- 價格 ¥ 605 ¥ 1411 ¥ 2016 ¥ 5040 ¥ 20160
- 欲了解實際交易價格和更多情況，請與當地經銷商聯系!
-
產品包裝(模擬)
-
產品包裝(模擬)
-
通過ISO 9001、ISO 13485質量體系認證
特異性
該抗體是針對CCND1的小鼠單克隆抗體。在免疫組織化學染色和免疫印跡實驗中能識別CCND1。
用法
免疫印跡：0.2-2μg/mL;1:500-5000
免疫組織化學：5-20μg/mL;1:50-200
免疫細胞化學：5-20μg/mL;1:50-200
最佳稀釋倍數最終由用戶決定。
儲存
經常使用則4°C保存。-20°C保存不超過兩年。避免反復凍融。
穩定性
熱穩定性以損失率顯示。損失率是由加速降解試驗決定，具體方法如下：在37°C孵育48小時，沒有顯著的降解或者沉淀產生。保質期內，在適當的條件下存儲，損失率低于5%。
贈品
增值服務
相關產品
| 編號 | 適用物種：Homo sapiens (Human，人) | 應用(僅供研究使用，不用于臨床診斷！) |
| RPA585Hu01 | 細胞周期素D1(CCND1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA585Hu02 | 細胞周期素D1(CCND1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA585Hu01 | 細胞周期素D1(CCND1)多克隆抗體 | WB |
| MAA585Hu22 | 細胞周期素D1(CCND1)單克隆抗體 | WB; IHC; ICC; IP. |
| SEA585Hu | 細胞周期素D1(CCND1)檢測試劑盒(酶聯免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMA585Hu | 細胞周期素D1(CCND1)等多因子檢測試劑盒(流式熒光發光法) | FLIA Kit for Antigen Detection. |
| KSA585Hu01 | 細胞周期素D1(CCND1)檢測試劑盒DIY材料(酶聯免疫吸附試驗法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻
| 雜志 | 參考文獻 |
| Biochemical Pharmacology | Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells [ScienceDirect: S0006295211002097] |
| Leukemia & Lymphoma | The nanoparticulate Quillaja saponin KGI exerts anti-proliferative effects by down-regulation of cell cycle molecules in U937 and HL-62 human leukemia cells [Pubmed: 24138332] |
| The Journal of Clinical Endocrinology and Metabolism | Antiproliferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down-regulation of cyclin-D1. [Pubmed: 23969186] |
| Nutrition and Cancer | Common Food Additive Carrageenan Stimulates Wnt/ β-Catenin Signaling in Colonic Epithelium by Inhibition of Nucleoredoxin Reduction [Pubmed:24328990] |
| The International Journal of Biochemistry &?Cell?Biology | MicroRNA-149 is epigenetically silenced tumor-suppressive microRNA, involved in cell proliferation and downregulation of AKT1 and cyclin D1 in human … [pubmed:27783537] |
| Scientific Reports | Is there an association between enhanced choline and β-catenin pathway in breast cancer? A pilot study by MR Spectroscopy and ELISA. [pubmed:28533512] |
| Investigational new drugs | Development of a dietary formulation of the SHetA2 chemoprevention drug for mice. [pubmed:29273857] |
| Biochemical Pharmacology | Metronomic vinorelbine is directly active on Non Small Cell Lung Cancer cells and sensitizes the EGFRL858R/T790M cells to reversible EGFR tyrosine kinase?… [Pubmed:29660315] |
| Apoptosis | Licarin A induces cell death by activation of autophagy and apoptosis in non-small cell lung cancer cells [Pubmed:29468481] |
| Oncology?Reports | Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo [Pubmed:29517106] |
| Oncology Reports | Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo [Pubmed:29517103] |
| Scientific Reports | Is there an association between enhanced choline and β-catenin pathway in breast cancer? A pilot study by MR Spectroscopy and ELISA [Pubmed: 28533512] |
| Middle East Journal of Rehabilitation and Health | Antiapoptotic Effects of Continuous Training and Selenium Consumption on the Liver Tissue of Cadmium-Exposed Rats [Pubmed: 10.5812/mejrh.91278] |
| European journal of medicinal chemistry | Synthesis of novel S-linked dihydroartemisinin derivatives and evaluation of their anticancer activity [Pubmed: 31216504] |
留言咨詢
